Global Markets for Treatments for Syndromes of Dementia and Movement Disorders

Published by: BCC Research

Published: Sep. 1, 2012 - 261 Pages

Table of Contents

CHAPTER 1 INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC RESEARCH REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS)

SUMMARY FIGURE GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS)

CHAPTER 3 OVERVIEW

THE BRAIN

CEREBRAL CORTEX

BRAIN STEM

SPINAL CORD

NEUROTRANSMITTERS

CLASSIFICATION OF NEURODEGENERATIVE DISORDERS

TABLE 1 CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE

NEURODEGENERATIVE DISORDERS

ALZHEIMER'S DISEASE

LEWY BODY DEMENTIA

PICK'S DISEASE

HUNTINGTON'S DISEASE

CORTICAL BASAL GANGLIONIC DEGENERATION

PARKINSON'S DISEASE

MULTIPLE SYSTEM ATROPHY

PROGRESSIVE SUPRANUCLEAR PALSY

HALLERVORDEN-SPATZ DISEASE

DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS

DIAGNOSTIC TESTS FOR PARKINSON'S

DIAGNOSTIC TESTS FOR ALZHEIMER'S

DIAGNOSTIC TESTS FOR PICK'S DISEASE

DIAGNOSTIC TESTS FOR MULTIPLE SYSTEM ATROPHY

DIAGNOSTIC TESTS FOR PROGRESSIVE SUPRANUCLEAR PALSY

DIAGNOSTIC TESTS FOR CORTICAL BASAL GANGLIONIC DEGENERATION

DIAGNOSTIC TESTS FOR LEWY BODY DEMENTIA

DIAGNOSTIC TESTS FOR HALLERVORDEN-SPATZ DISEASE

CHAPTER 4 REGULATORY ASPECTS

INTRODUCTION

DRUG APPROVALS

TABLE 2 ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012

TABLE 3 PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS

TABLE 4 FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012

TABLE 5 FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012

REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND MOVEMENT DISORDER PRODUCTS

CHAPTER 5 NEW DEVELOPMENTS

TABLE 6 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2012

TABLE 7 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2011

TABLE 8 NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010

CHAPTER 6 GLOBAL MARKETS

MARKETS BY CLINICAL/PATHOLOGICAL FEATURE

MARKET OVERVIEW

MARKET REVENUES

TABLE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 1 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)

FIGURE 2 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011 (%)

MARKET BY DISEASE TYPE

MARKET OVERVIEW

MARKET REVENUES

TABLE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, THROUGH 2017 ($ MILLIONS)

FIGURE 3 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR NEURODEGENERATIVE DISORDERS, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011 (%)

FIGURE 4 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011 (%)

MARKET BY REGION

MARKET OVERVIEW

MARKET REVENUE

TABLE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 5 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 14 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)

FIGURE 6 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011 (%)

MARKETS BY TECHNOLOGY

MARKET OVERVIEW

MARKET REVENUE

TABLE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS)

FIGURE 7 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 16 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)

FIGURE 8 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011 (%)

CHAPTER 7 MARKET FOR DRUG PRODUCTS USED TO TREAT PROGRESSIVE

DEMENTIA MARKET BY DISEASE TYPE

ALZHEIMER'S DISEASE

LEWY BODY DEMENTIA

PICK'S DISEASE

MARKET OVERVIEW

MARKET REVENUE

TABLE 17 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA, THROUGH 2017 ($ MILLIONS)

FIGURE 9 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 18 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY DISEASE TYPE, 2011 (%)

FIGURE 10 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY DISEASE TYPE, 2011 (%)

MARKET BY REGION

MARKET OVERVIEW

MARKET REVENUE

TABLE 19 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 11 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 20 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2011 (%)

FIGURE 12 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY REGION, 2011 (%)

REGIONAL MARKETS BY DISEASE TYPE

ALZHEIMER'S DISEASE

TABLE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER’S DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 13 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER’S DISEASE BY REGION, 2010-2017 ($ MILLIONS)

LEWY BODY DEMENTIA

TABLE 22 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 14 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA BY REGION, 2010-2017 ($ MILLIONS)

PICK'S DISEASE

TABLE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PICK’S DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 15 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PICK’S DISEASE BY REGION, 2010-2017 ($ MILLIONS)

MARKET BY TECHNOLOGY

SMALL MOLECULES

MONOCLONAL ANTIBODIES

OTHERS

Immunization Strategy

Tau Tangling Inhibitors

Aminothienopyridazine (ATPZ) Analogues

Biomarkers

Stem Cells

MARKET OVERVIEW

MARKET REVENUE

TABLE 24 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS)

FIGURE 16 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 25 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2011 (%)

FIGURE 17 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA BY TECHNOLOGY, 2011 (%)

INDUSTRY STRUCTURE

LEADING MANUFACTURERS OF ALZHEIMER'S DRUGS

TABLE 26 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT ALZHEIMER'S DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF ALZHEIMER'S DRUGS

TABLE 27 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER’S DISEASE, 2011 (%)

FIGURE 18 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT ALZHEIMER’S DISEASE, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT LEWY BODY DEMENTIA

TABLE 28 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT LEWY BODY DEMENTIA

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT LEWY

BODY DEMENTIA

TABLE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA, 2011 (%)

FIGURE 19 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT LEWY BODY DEMENTIA, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT PICK'S DISEASE

TABLE 30 LEADING MANUFACTURERS/ DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT PICK’S DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT PICK'S DISEASE

TABLE 31 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PICK’S DISEASE, 2011 (%)

FIGURE 20 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PICK’S DISEASE, 2011 (%)

CHAPTER 8 MARKET FOR DRUGS TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES

MARKET BY DISEASE TYPE

HUNTINGTON'S DISEASE

CORTICOBASAL GANGLIONIC DEGENERATION

MARKET OVERVIEW

TABLE 32 CHDI FOUNDATIONS’ KEY DEVELOPMENTS IN TREATING HUNTINGTON’S DISEASE

MARKET REVENUE

TABLE 33 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, THROUGH 2017 ($ MILLIONS)

FIGURE 21 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TYPE OF DISEASE, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 34 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%)

FIGURE 22 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY DISEASE TYPE, 2011 (%)

MARKET BY REGION

MARKET OVERVIEW

TABLE 35 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 23 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 36 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%)

FIGURE 24 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY REGION, 2011 (%)

REGIONAL MARKETS BY DISEASE TYPE

HUNTINGTON'S DISEASE

TABLE 37 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON’S DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 25 GLOBAL SALES OF DRUGS USED TO TREAT HUNTINGTON’S DISEASE BY REGION, 2010-2017 ($ MILLIONS)

CORTICOBASAL GANGLIONIC DEGENERATION

TABLE 38 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 26 GLOBAL SALES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION BY REGION, THROUGH 2017 ($ MILLIONS)

MARKET BY TECHNOLOGY

SMALL MOLECULES

MONOCLONAL ANTIBODIES

OTHERS

Stem Cells

Biomarkers

MARKET OVERVIEW

MARKET REVENUE

TABLE 39 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS)

FIGURE 27 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 40 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%)

FIGURE 28 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE DEMENTIA WITH OTHER NEUROLOGICAL ABNORMALITIES BY TECHNOLOGY, 2011 (%)

INDUSTRY STRUCTURE

LEADING MANUFACTURERS OF DRUGS USED TO TREAT HUNTINGTON'S DISEASE

TABLE 41 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON’S DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

HUNTINGTON'S DISEASE

TABLE 42 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HUNTINGTON'S DISEASE, 2011 (%)

FIGURE 29 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS FOR USED TO TREAT HUNTINGTON’S DISEASE, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT CORTICOBASAL

GANGLIONIC DEGENERATION

TABLE 43 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HUNTINGTON’S DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

CORTICOBASAL GANGLIONIC DEGENERATION

TABLE 44 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%)

FIGURE 30 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUGS USED TO TREAT CORTICOBASAL GANGLIONIC DEGENERATION, 2011 (%)

CHAPTER 9 MARKET FOR MOVEMENT DISORDER SYNDROMES

MARKET BY TYPE OF DISEASE

PARKINSON'S DISEASE

MULTIPLE SYSTEM ATROPHY

PROGRESSIVE SUPRANUCLEAR PALSY

HALLERVORDEN-SPATZ DISEASE

MARKET OVERVIEW

TABLE 45 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, THROUGH 2017 ($ MILLIONS)

FIGURE 31 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 46 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)

FIGURE 32 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2011 (%)

MARKETS BY REGION

MARKET OVERVIEW

MARKET REVENUE

TABLE 47 GLOBAL SALES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 33 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 48 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)

FIGURE 34 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY REGION, 2011 (%)

REGIONAL MARKETS BY DISEASE TYPE

PARKINSON'S DISEASE

TABLE 49 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 35 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON’S DISEASE BY REGION, 2010-2017 ($ MILLIONS)

MULTIPLE SYSTEM ATROPHY

TABLE 50 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 36 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY BY REGION, 2010-2017 ($ MILLIONS)

PROGRESSIVE SUPRANUCLEAR PALSY

TABLE 51 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 37 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY BY REGION, 2010-2017 ($ MILLIONS)

HALLERVORDEN-SPATZ DISEASE

TABLE 52 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, THROUGH 2017 ($ MILLIONS)

FIGURE 38 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE BY REGION, 2010-2017 ($ MILLIONS)

MARKET BY TECHNOLOGY

SMALL MOLECULES

MONOCLONAL ANTIBODIES

OTHERS

Tau Tangling Inhibitors

Biomarkers

Stem Cells

MARKET OVERVIEW

MARKET REVENUE

TABLE 53 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, THROUGH 2017 ($ MILLIONS)

FIGURE 39 GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2010-2017 ($ MILLIONS)

MARKET SHARE

TABLE 54 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)

FIGURE 40 GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY TECHNOLOGY, 2011 (%)

INDUSTRY STRUCTURE

LEADING MANUFACTURERS OF DRUGS USED TO TREAT PARKINSON'S DISEASE

TABLE 55 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PARKINSONfS DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

PARKINSON'S DISEASE

TABLE 56 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSONa€.S DISEASE, 2011 (%)

FIGURE 41 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PARKINSONfS DISEASE, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT MULTIPLE SYSTEM

ATROPHY

TABLE 57 LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO TREAT MULTIPLE SYSTEM ATROPHY

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

MULTIPLE SYSTEM ATROPHY

TABLE 58 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)

FIGURE 42 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM ATROPHY, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT PROGRESSIVE

SUPRANUCLEAR PALSY

TABLE 59 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

PROGRESSIVE SUPRANUCLEAR PALSY

TABLE 60 MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)

FIGURE 43 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011 (%)

LEADING MANUFACTURERS OF DRUGS USED TO TREAT HALLERVORDEN-SPATZ

DISEASE

TABLE 61 LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO TREAT HALLERVORDEN-SPATZ DISEASE

MARKET SHARES OF LEADING MANUFACTURERS OF DRUGS USED TO TREAT

HALLERVORDEN-SPATZ DISEASE

TABLE 62 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)

FIGURE 44 MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011 (%)

CHAPTER 10 PATENT ANALYSIS

PATENTS ISSUED BY YEAR

TABLE 63 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (NO.)

FIGURE 45 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010—MARCH 2012 (NO.)

FIGURE 46 PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012 (%)

PATENTS BY DISEASE CATEGORY

TABLE 64 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)

FIGURE 47 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012 (NO.)

PATENTS BY DISEASE TYPE

SYNDROMES OF DEMENTIA

TABLE 65 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012 (NO.)

FIGURE 48 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012* (NO.)

MOVEMENT DISORDER SYNDROMES

TABLE 66 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)

FIGURE 49 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012 (NO.)

PATENTS BY COUNTRY

SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA)

TABLE 67 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

FIGURE 50 U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

TABLE 68 U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (%)

MOVEMENT DISORDER SYNDROMES

TABLE 69 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

FIGURE 51 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (NO.)

TABLE 70 U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY PATENT HOLDER’S COUNTRY, 2010-MARCH 2012 (%)

PATENTS BY COMPANY

SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA)

TABLE 71 NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012 (NO.)

MOVEMENT DISORDER SYNDROMES

TABLE 72 U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES BY COMPANY, 2010-MARCH 2012 (NO.)

CHAPTER 11 CURRENT SITUATION

MARKET TRENDS

SYNDROMES OF DEMENTIA

Market Drivers

MOVEMENT DISORDER SYNDROMES

Market Drivers

OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA

AND MOVEMENT DISORDERS

OTHER FACTORS AFFECTING THE MARKET

COLLABORATIONS/MERGERS AND ACQUISITIONS

CHAPTER 12 COMPANY PROFILES

ABBOTT LABORATORIES

ABLYNX NV

ACCERA INC.

ACORDA THERAPEUTICS INC.

ACTAVIS ELIZABETH

AFFIRIS AG

ALLIANCE PHARMA PLC

ALLON THERAPEUTICS INC.

ALPHAPHARM

ALZHYME LTD.

AMERICAN REGENT INC.

APOTEX INC.

APOTHECA INC.

ASTELLAS PHARMA INC.

ASTRAZENECA GMBH

AUROBINDO PHARMA LTD.

BAXTER INTERNATIONAL INC.

BELLUS HEALTH INC.

BOEHRINGER INGELHEIM LTD.

BRISTOL-MYERS SQUIBB

BRYANT RANCH PREPACK

CADILA HEALTHCARE LTD.

CARACO PHARMACEUTICAL LABORATORIES

CARDINAL HEALTH

CELLZOME AG

CIPLA LTD.

COGNITION THERAPEUTICS INC.

COLUCID PHARMACEUTICALS INC.

COMENTIS INC.

CORTEX PHARMACEUTICALS

CYTOS BIOTECHNOLOGY AG

DAIICHI SANKYO CO. LTD.

DR. REDDY'S LABORATORIES LTD.

EISAI CO. LTD.

ELAN PHARMA INTERNATIONAL LTD.

ELI LILLY AND CO.

ENDO PHARMACEUTICALS INC.

ENVIVO PHARMACEUTICALS

EVOTEC AG

EPITOMICS INC.

EXONHIT THERAPEUTICS SA

FOREST LABORATORIES INC.

GLAXOSMITHKLINE PLC

GLENMARK GENERICS LTD.

H. LUNDBECK A/S

HAMELN PHARMACEUTICALS LTD.

HELICON THERAPEUTICS INC.

HOSPIRA INC.

INTELLECT NEUROSCIENCES INC.

INTRA-CELLULAR THERAPIES INC.

JAZZ PHARMACEUTICALS PLC

MAJOR PHARMACEUTICALS

MEDIVATION INC.

MEMORY PHARMACEUTICALS CORP.

MERCK SERONO

MERCK SHARP & DOHME LTD.

MERZ PHARMA GMBH & CO KGAA

MITHRIDION INC.

MYLAN PHARMACEUTICALS

NEUREN PHARMACEUTICALS LTD.

NEURO-HITECH INC.

NEUROPTIX CORP.

NEUROSEARCH A/S

NEWRON PHARMACEUTICALS SPA

NOSCIRA SA

NOVARTIS AG

NYMOX PHARMACEUTICAL CORP.

ORCHID CHEMICALS & PHARMACEUTICALS LTD.

ORION CORP.

ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.

PAR PHARMACEUTICALS

PERRIGO CO.

PFIZER INC.

PHARNEXT

PHYSICIANS TOTAL CARE INC.

PLIVA HRVATSKA D.O.O.

PRASCO LABORATORIES

RANBAXY LABORATORIES LTD.

ROCHE HOLDING LTD.

ROXANE LABORATORIES INC.

SANDOZ INTERNATIONAL GMBH

SANOFI

SANTHERA PHARMACEUTICALS

SHIONOGI & CO.

STADA ARZNEIMITTEL AG

SUN PHARMA

TAJ PHARMACEUTICALS LTD.

TAKEDA PHARMACEUTICAL CO. LTD.

TERCICA INC.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

TORRENT PHARMA

UCB SA

UDL LABORATORIES

UPSHER-SMITH LABORATORIES

VALEANT PHARMACEUTICALS

VERNALIS PLC

WATSON PHARMACEUTICALS INC.

WEST-WARD PHARMACEUTICAL

CHAPTER 13 APPENDIX I: ABBREVIATIONS

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.